GlassScriptPhysician profile
Steven D Klein
NPI 1922054733
$9,205.37
in general payments reported to CMS, 2019-2025
39 companies · $1,492 in 2025
The $1,492 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $621 · 2020: $433 · 2021: $859 · 2022: $1,750 · 2023: $2,008 · 2024: $2,042 · 2025: $1,492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,449 · Education: $92.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,449.41 |
| Education | $92.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,941.86 | 2019-2025 | |
| Boston Scientific Corporation | $1,321.08 | 2019-2025 | Exalt Model D, Axonics, Axios |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $737.32 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Medtronic, INC. | $408.46 | 2022-2024 | Gi Genius, Bravo, Interstim |
| Gilead Sciences, INC. | $403.17 | 2020-2024 | |
| Janssen Biotech, INC. | $282.35 | 2019-2025 | Stelara, Tremfya, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $270.03 | 2019-2025 | Entyvio, Gattex |
| E.R. Squibb & Sons, L.L.C. | $249.63 | 2021-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $212.06 | 2023-2025 | Dupixent |
| Conmed Corporation | $202.83 | 2024 | Conmed Generators, Conmed Hemostasis, Conmed Biliary |
| Ferring Pharmaceuticals INC. | $197.11 | 2020-2022 | |
| Madrigal Pharmaceuticals | $193.76 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $184.91 | 2025 | Voquezna |
| Celgene Corporation | $174.43 | 2022-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $137.36 | 2021-2024 | Dificid |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $132.58 | 2021-2023 | Givlaari |
| Ardelyx, INC. | $121.88 | 2023-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $119.88 | 2024-2025 | Zenpep, Vowst |
| Lilly USA, LLC | $113.36 | 2024-2025 | Omvoh |
| Pfizer INC. | $90.86 | 2020-2025 | |
| Qol Medical, LLC | $78.93 | 2022-2025 | Sucraid, Sucraid |
| Nestle Healthcare Nutrition INC. | $71.36 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $63.91 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $55.67 | 2025 | |
| Genzyme Corporation | $54.14 | 2023-2024 | |
| Daiichi Sankyo INC. | $52.85 | 2022-2023 | Injectafer |
| Intra-Sana Laboratories | $48.91 | 2021-2022 | |
| Pentax of America, INC. | $46.64 | 2020-2021 | |
| Fresenius Kabi USA, LLC | $34.97 | 2023-2024 | Idacio |
| Braintree Laboratories, INC. | $34.27 | 2023 | Sutab |
| Janssen Pharmaceuticals, INC | $31.85 | 2019 | |
| Celltrion USA INC. | $31.37 | 2024-2025 | Zymfentra, Vegzelma |
| Ipsen Biopharmaceuticals, INC | $20.78 | 2024 | Iqirvo |
| Micro-Tech Endoscopy USA, INC. | $16.89 | 2022 | |
| Exact Sciences Corporation | $16.42 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $15.14 | 2021 | |
| Ambu INC. | $13.20 | 2021 | |
| Alexion Pharmaceuticals, INC. | $11.86 | 2021 | |
| Alfasigma USA, INC. | $11.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.